Improved treatment satisfaction in patients with type 1 diabetes treated with insulin glargine 100 U/mL versus neutral protamine Hagedorn insulin: An exploration of key predictors from two randomized controlled trials

Aim: Investigate contributors to treatment satisfaction in type 1 diabetes (T1D). Methods: Post-hoc analysis using the Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) in 771 T1D patients from two 28-week trials comparing once-daily insulin glargine 100 U/mL (Gla-100) with once- or twice-daily NPH neutral protamine Hagedorn (NPH) insulin. Results: Gla-100 was associated with a significant improvement in treatment satisfaction versus NPH (overall population adjusted mean [standard error] DTSQs change from baseline: +1.13 [0.30] versus -0.04 [0.31]; p = 0.006). In the overall population, treatment satisfaction improvement with all insulin regimens was related to less frequent severe hypoglycemia (coefficient 0.077; p = 0.040) and HbAlc reduction (-0.066; p = 0.082). By treatment regimen, relationships between treatment satisfaction and these outcomes approached or attained statistical significance for NPH insulin, but not Gla-100. In the overall population, predictors of treatment satisfaction improvement included: Gla-100 treatment (estimate 1.17, p = 0.006), lower baseline DTSQs (-0.57, p < 0.001), study (-1.01, p = 0.019), lower severe hypoglycemia rate (0.17, p = 0.012), and higher baseline HbAlc (0.44, p = 0.014). By treatment regimen, these predictors remained significant for NPH insulin. Conclusions: Gla-100 resulted in a significant improvement in treatment satisfaction versus NPH insulin, independent of baseline disease characteristics and clinical outcomes. (C) 2017 Elsevier Inc. All rights reserved.